{"prompt": "['Alliance A221504', '18. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase', 'III study of maintenance pemetrexed versus placebo immediately after induction treatment with', 'pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol.', '2013;31(23):2895-2902.', '19. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-', 'small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus', 'etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol.', '2000;18(3):623-631.', '20. Beitz J, Gnecco C, Justice R. Quality of life endpoints in cancer clinical trials: the U.S. Food and Drug', 'Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7-9.', '21. ASCO. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J', 'Clin Oncol. 1996;14:671-679.', '22. Galetta D, Pisconti S, Cinieri S, et al. Induction pemetrexed and cisplatin followed by maintenance', 'pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance', 'bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-', 'squamous non-small-cell lung cancer (ERACLE). Clin Lung Cancer. 2011;12(6):402-406.', '23. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study', 'group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line', 'chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217-3224.', '24. Zylla D, Kuskowski M, Gupta K, Gupta P. Association of opioid requirement and cancer pain with', 'survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113(S1):ii109-116.', \"25. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Efficacy of orally administered\", 'methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend.', '1998;52(2):161-165.', \"26. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. Effects of subcutaneous\", 'methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized', 'placebo-controlled trial. J Pharmacol Exp Ther. 2002;300(1): 118-123.', '27. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced', 'constipation in patients with noncancer pain. N Engl JMed.2014;370(25):2387-2396', '28. Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs.', '2015;75(4):419-425', '29. Loprinzi CL, Love RR, Therneau TM, Verma AK. Inhibition of human skin ornithine decarboxylase', 'activity by oral alpha-difloromethylornithine. Prev Med. 1989;18(5):775.', \"30. Loprinzi CL, Messing EM, O'Fallon JR, et al. Toxicity evaluation of difluoromethylornithine: doses\", 'for chemoprevention trials. Cancer Epidemiol Biomarkers Prev. 1996;5(5):371-374.', '31. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced', 'promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.', 'Br J Cancer. 2007;97(11):1523-1531.', '32. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-', 'induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72(1-2):3-11,', '33. Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and', 'impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014;in press.', '58', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', '34. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of', 'estrogen receptor activity in MCF-7 cells. Mol Cancer Ther. 2006;5(3):611-620.', '35. Koo KL, Tejwani GA, Abou-Issa H. Relative efficacy of the opioid antagonist, naltrexone, on the', 'initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res. 1996;16(4A):1893-', '1898.', '36. Zagon IS, McLaughlin PJ. Opioid antagonists inhibit the growth of metastatic murine neuroblastoma.', 'Cancer Lett. 1983;21(1):89-94.', '37. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science.', '1983;221(4611):671-673', '38. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the', 'mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor', 'growth, and metastasis. Anesthesiol. 2012;116(4):857-867.', '39. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling', 'in mouse retinal endothelial cells. Curr Neurovasc Res. 2006;3(3):171-180.', '40. Luk K, Boatman S, Johnson KN, et al. Influence of morphine on pericyte-endothelial interaction:', 'implications for antiangiogenic therapy. J Oncol. 2012;2012:458385.', '41. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of', 'vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell', 'Mol Biol. 2007;37(2):222-231.', '42. Weber ML, Farooqui M, Nguyen J, et al. Morphine induces mesangial cell proliferation and', 'glomerulopathy via kappa-opioid receptors. Am J Physiol Renal Physiol. 2008;294(6):F1388-1397.', '43. Suzuki M, Chiwaki F, Sawada Y, et al. Peripheral opioid antagonist enhances the effect of anti-tumor', 'drug by blocking a cell growth-suppressive pathway in vivo. PLoS One. 2015;10(4):e0123407.', '44. Halabi S, Lin CY, Kelly WK, et al. Updated Prognostic Model for Predicting Overall Survival in First-', 'Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol.', '2014;32(7):671-677.', '45. Lissoni P, Meregalli S, Fossati V, et al. Radioendocrine therapy of brain tumors with the long acting', 'opioid antagonist naltrexone in association with radiotherapy. Tumori. 1993;79(3):198-201', '46. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK. Chemical splanchnicectomy in', 'patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg.', '1993;217(5):447-455.', '47. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system', 'compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-', 'related toxicity, and survival. J Clin Oncol. 2002;20(19):4040-4049.', '48. Zylla D, Steele G, Shapiro A, Richter S, Gupta P. Impact of opioid use on health care utilization and', 'survival in patients with newly diagnosed stage IV malignancies. Support Care Cancer. 2018;', '26(7):2259-66.', '49. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased mu-opioid receptor expression', 'in metastatic lung cancer. Br J Anaesth.2014;113(Suppl 1):i103-108.', '50. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose', 'on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900-908.', '59', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}